# Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients

> **NCT07397481** · PHASE4 · COMPLETED · sponsor: **Kafrelsheikh University** · enrollment: 40 (actual)

## Conditions studied

- Liver Cirrhosis
- Arterial Hypertension

## Interventions

- **DRUG:** Nebivolol 5 mg
- **DRUG:** Carvedilol 12.5 mg
- **DRUG:** Nebivolol 2.5 mg
- **DRUG:** Carvedilol 6.25 mg

## Key facts

- **NCT ID:** NCT07397481
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-01
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07397481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07397481, "Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07397481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*